Periodontal Health in Patients on Denosumab (PoD)
Research type
Research Study
Full title
Periodontal Health in Patients on Denosumab
IRAS ID
245083
Contact name
Shauna Culshaw
Contact email
Sponsor organisation
NHS GGC R&D
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
Severe gum disease affects 10% of the population and causes tooth loss, compromising oral health and quality of life. The tooth loss follows bone loss caused by 'friendly fire' from the immune system as it fights bacteria on the tooth. We are interested in a drug called Denosumab which is used to stop bone loss in osteoporosis (brittle bones). Denosumab might stop bone loss but it might also make patients more susceptible to infections in the jaw bone. We seek to examine, in detail, the mouths of patients who start taking Denosumab. This will potentially help both osteoporosis and gum disease patients.
REC name
West Midlands - Coventry & Warwickshire Research Ethics Committee
REC reference
20/WM/0104
Date of REC Opinion
1 Jun 2020
REC opinion
Further Information Favourable Opinion